Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 888 results for community guidance

  1. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

    Technology appraisal guidance
    Published
    8 June 2015
    View recommendations

    Sections for TA339

  2. What is the prevalence and incidence of post-COVID-19 syndrome in patients who have received single, double, or boosted doses of the approved vaccinations in the UK? Does this vary across different population groups (for example in black, Asian and minority ethnic group communities)?

    minority ethnic group communities)? Any explanatory notes(if applicable) Source guidance details Comes from...

    Research recommendation
    Published
    12 November 2021

  3. Cost utility:- What is the cost utility of increasing the offer or uptake of HIV testing in different settings, for different types of tests, using different strategies (for example opt-in or opt-out approaches) and in areas and groups with different background prevalence?

    cost effective services for their local communities. Source guidance details Comes from guidance HIV testing:...

    Research recommendation
    Published
    14 February 2017

  4. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

    Medtech innovation briefing
    Published
    13 September 2017

  5. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA392

  6. Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

    Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.

    Technology appraisal guidance
    Published
    15 December 2021
    View recommendations

    Sections for TA754

  7. Prontosan for treating acute and chronic wounds (HTG616)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

    HealthTech guidance
    Published
    8 March 2022
    View recommendations

    Sections for HTG616

  8. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

  9. Digital platforms to support cardiac rehabilitation: early value assessment (HTG764)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

    HealthTech guidance
    Published
    4 December 2025
    View recommendations

    Sections for HTG764

  10. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA474

  11. Medical technologies evaluation programme methods guide (PMG33)

    This methods guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it

  12. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

    HealthTech guidance
    Published
    21 October 2024
    View recommendations

    Sections for HTG729

  13. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

    NICE guideline
    Last updated
    8 March 2024

    Sections for NG122

  14. Butterfly iQ+ for diagnostic ultrasound imaging (MIB254)

    NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .

    Medtech innovation briefing
    Published
    4 March 2021

  15. Biopatch for venous or arterial catheter sites (MIB117)

    NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .

    Medtech innovation briefing
    Published
    9 August 2017